Different Exercising Intensities and Frequencies of Exercise on Depressive Mood and Insomnia
17 de janeiro de 2022 atualizado por: The University of Hong Kong
Effects of Different Exercising Intensities and Frequencies of Walking Exercise on Depressive Mood and Insomnia in Older Adults
Aerobic exercise intervention for depression was conventionally recommended three times weekly with moderate intensity in previous studies, but little is known about the training effect of aerobic exercise at low frequency and vigorous intensity.
The purpose of this study is to compare the training effect of aerobic exercise at different exercising frequencies and intensities on older adults with comorbid insomnia and depressive symptoms.
In this study, the investigators will investigate two types of aerobic exercise (i.e., vigorous-intensity exercise and moderate-intensity exercise) under different exercising frequencies (i.e., regular exercising pattern and weekend warrior).
Individuals with chronic insomnia and depressive symptoms will be recruited and randomly allocated into 5 groups: 1) attention control group (stretching exercise), 2) moderate intensity exercise performed thrice weekly (MIE×3/wk), 3) moderate intensity exercise performed once weekly (MIE×1/wk), 4) vigorous intensity exercise performed thrice weekly (VIE×3/wk), and 5) vigorous intensity exercise performed once weekly (VIE×1/wk).
Intervention will be maintained for 12 weeks.
Outcome assessments will be conducted at baseline, 6 weeks and 12 weeks after the intervention.
Outcomes including depressive status, chronic insomnia, objective sleep quality and pattern (measured by Actigraphy), subjective sleep quality (measured by Epworth sleepiness scale, insomnia severity index, PSQI), anxiety status (measured by HADS and GAD-7), quality of life (measured by SF-12), attention level (measured by computer attention test), exercise enjoyment (measured by physical activity enjoyment scale), habitual physical activity level (measured by IPAQ), aerobic fitness (measured by metabolic cart), body adiposity (measured by DXA), blood chemistry, adherence, medication usage, and adverse events will be measure in this study.
This proposed study will provide pilot evidence for the benefits, effectiveness, safety, adherence, and sustainability of low-frequency vigorous aerobic exercise.
the investigators expect the low-frequency exercise modality will enhance the practical suitability of aerobic exercise and will provide evidence for weekend warrior aerobic training strategy as a new exercise option in the management of elderly insomnia and depression.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
75
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Hong Kong, Hong Kong
- LKS Faculty of Medicine
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
50 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- borderline abnormal depression with score above 8 out of 21 on Hospital Anxiety and Depression Scale (HADS),
- chronic insomnia according to the fifth edition of the diagnostic and statistical manual of mental disorder (DSM-5),
- Cantonese, Mandarin or English speaking, and 4) age 50 or above. To enhance generalizability, males and females will be recruited.
Exclusion Criteria:
- contraindications to participating in physical exercise;
- regular exercise habit in the past three months (i.e.,>75 minutes of vigorous-intensity exercise weekly or >150 minutes of moderate-intensity exercise weekly);
- any pre-existing medical or physical issues that affect the experimental test and exercise intervention;
- diagnosis with psychosis, schizophrenia or bipolar disorder;
- currently receiving non-medication treatment for depression or insomnia, such as mindfulness training or cognitive behavior therapy;
- shift worker or other commitment that interferes with the regular sleep pattern at night; and
- abnormal heart's electrical activity according to the exercise electrocardiography (ECG) test, such as irregular heartbeat, arrhythmia, and myocardial infarction.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Attention control
Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
|
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly.
All walking exercise session will be performed on motor-driven treadmill.
Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs).
Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs).
Warm-up and cool-down will be provided before and after the training.
Participants who failed to achieve 80% attendance will be excluded from the study.
All exercise sessions were supervised by qualified athletic coach.
|
|
Comparador Ativo: Moderate-intensity walking exercise ×3/wk
Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
|
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly.
All walking exercise session will be performed on motor-driven treadmill.
Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs).
Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs).
Warm-up and cool-down will be provided before and after the training.
Participants who failed to achieve 80% attendance will be excluded from the study.
All exercise sessions were supervised by qualified athletic coach.
|
|
Comparador Ativo: Moderate-intensity walking exercise ×1/wk
Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
|
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly.
All walking exercise session will be performed on motor-driven treadmill.
Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs).
Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs).
Warm-up and cool-down will be provided before and after the training.
Participants who failed to achieve 80% attendance will be excluded from the study.
All exercise sessions were supervised by qualified athletic coach.
|
|
Comparador Ativo: Vigorous-intensity walking exercise ×3/wk
Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
|
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly.
All walking exercise session will be performed on motor-driven treadmill.
Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs).
Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs).
Warm-up and cool-down will be provided before and after the training.
Participants who failed to achieve 80% attendance will be excluded from the study.
All exercise sessions were supervised by qualified athletic coach.
|
|
Comparador Ativo: Vigorous-intensity walking exercise ×1/wk
Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
|
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly.
All walking exercise session will be performed on motor-driven treadmill.
Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs).
Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs).
Warm-up and cool-down will be provided before and after the training.
Participants who failed to achieve 80% attendance will be excluded from the study.
All exercise sessions were supervised by qualified athletic coach.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Level of depression
Prazo: After completion of the 12 weeks intervention
|
Hospital Anxiety and Depression Scale (HADS) will be used to measure the level of depression
|
After completion of the 12 weeks intervention
|
|
Remission rate of insomnia
Prazo: After completion of the 12 weeks intervention
|
Brief insomnia questionnaire (BIQ) will be employed to diagnose the chronic insomnia based on the DSM-5 criteria.
|
After completion of the 12 weeks intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Subjective sleep data
Prazo: After completion of the 12 weeks intervention
|
The Epworth sleepiness scale, insomnia severity index, and Pittsburgh sleep quality index (PSQI) will be used to measure the sleep quality.
|
After completion of the 12 weeks intervention
|
|
Objective sleep data
Prazo: After completion of the 12 weeks intervention
|
Actigraphy will be used to measure the sleep quality and pattern.
|
After completion of the 12 weeks intervention
|
|
Change in dose of Sleep Medication
Prazo: After completion of the 12 weeks intervention
|
The dose of sleep medication used by the subjects changes after intervention.
|
After completion of the 12 weeks intervention
|
|
7-day Sleep Diary
Prazo: After completion of the 12 weeks intervention
|
Self-recorded sleep parameters (sleep onset latency, sleep efficiency, total sleep time, wake time after sleep onset, number of awakening and average awaken time)
|
After completion of the 12 weeks intervention
|
|
Treatment response rate
Prazo: After completion of the 12 weeks intervention
|
The percentage of participants that have their Score of Pittsburgh Sleep Quality Index reduced by at least 5 points
|
After completion of the 12 weeks intervention
|
|
Body composition
Prazo: After completion of the 12 weeks intervention
|
Body lean mass, fat mass, and bone density will be measured by dual-energy X-ray absorptiometry
|
After completion of the 12 weeks intervention
|
|
Maximal oxygen consumption
Prazo: After completion of the 12 weeks intervention
|
Metabolic cart will measure the maximal oxygen consumption during the maximal exercise test
|
After completion of the 12 weeks intervention
|
|
Anxiety level
Prazo: After completion of the 12 weeks intervention
|
Anxiety level will be measured by HASD and General Anxiety Disorder-7.
|
After completion of the 12 weeks intervention
|
|
Severity of depression
Prazo: After completion of the 12 weeks intervention
|
PHQ-9 will be used to examine the severity of depression.
|
After completion of the 12 weeks intervention
|
|
Blood chemistry tests
Prazo: After completion of the 12 weeks intervention
|
biological markers related to depression and sleep will be measured by enzyme-linked immunosorbent assa
|
After completion of the 12 weeks intervention
|
|
Subjectively measured quality of life
Prazo: After completion of the 12 weeks intervention
|
Measured by the 12-item Short Form Survey, scores range from 0 to 100, higher scores indicating better physical and mental health functioning
|
After completion of the 12 weeks intervention
|
|
Enjoyment of exercise intervention
Prazo: After completion of the 12 weeks intervention
|
Physical activity enjoyment scale will be used to test the subject's perception of the exercise, higher scores reflect greater levels of enjoyment
|
After completion of the 12 weeks intervention
|
|
Attention level
Prazo: After completion of the 12 weeks intervention
|
Computer attention test in PsychoPy v2 software will be employed to measure the attention.
|
After completion of the 12 weeks intervention
|
|
Habitual physical activity
Prazo: After completion of the 12 weeks intervention
|
Habitual physical activity will be measured by IPAQ
|
After completion of the 12 weeks intervention
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
31 de janeiro de 2019
Conclusão Primária (Real)
30 de setembro de 2021
Conclusão do estudo (Real)
31 de outubro de 2021
Datas de inscrição no estudo
Enviado pela primeira vez
17 de abril de 2020
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de abril de 2020
Primeira postagem (Real)
21 de abril de 2020
Atualizações de registro de estudo
Última Atualização Postada (Real)
1 de fevereiro de 2022
Última atualização enviada que atendeu aos critérios de controle de qualidade
17 de janeiro de 2022
Última verificação
1 de julho de 2021
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- DI
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .